Diabetes

health

Doctors probe whether COVID-19 is causing diabetes

(Reuters) – Mario Buelna, a healthy 28-year-old father, caught a fever and started having trouble breathing in June. He soon tested positive for COVID-19.

The Simis family, Atticus, Sarah, Arthur and Ophelia, pose for a photo in Gardnerville, Nevada, September 24, 2020. Simis family/Handout via REUTERS

Weeks later, after what had seemed like a recovery, he felt weak and started vomiting. At 3 a.m. on Aug. 1, he passed out on the floor of his home in Mesa, Arizona.

Paramedics rushed him to a nearby hospital, where doctors put him in intensive care after saving him from a coma. They told him he could have died. Their diagnosis – type 1 diabetes – stunned and frightened him. He had no history of the disease.

“COVID triggered it,” Buelna said the doctors told him.

Buelna’s ordeal and similar cases reflect a new worry about the dangerous relationship between diabetes and COVID-19 that’s being urgently studied by doctors and scientists around the world. Many experts are convinced that COVID-19 can trigger the onset of diabetes – even in some adults and children who do not have the traditional risk factors.

It’s already been well-documented that people with diabetes face much higher risks of severe illness or death if they contract COVID-19. In July, U.S. health officials found that nearly 40% of people who have died with COVID-19 had diabetes. Now, cases like Buelna’s suggest the connection between the diseases runs both ways.

“COVID could be causing diabetes from scratch,” said Dr. Francesco Rubino, a diabetes researcher and chair of metabolic and bariatric surgery at King’s College London.

Rubino is leading an international team that is collecting patient cases globally to unravel one of the biggest mysteries of the pandemic. Initially, he said, more than 300 doctors have applied to share cases for review, a number he expects to grow as infections flare up again.

“These cases are coming from every corner of the world and every continent,” Rubino told Reuters.

In addition to the global registry, the U.S. National Institutes of Health is financing research into how the coronavirus may cause high blood sugars and diabetes.

In these situations, symptoms can escalate quickly and become life threatening. These cases may take months to surface after exposure to COVID-19, so the full extent of the problem and the long-term ramifications may not be known until well into next year. More intensive research is needed to definitively prove, beyond the mounting anecdotal evidence, that COVID-19 is triggering diabetes on a wide scale.

“We have more questions than answers right now,” said Dr. Robert Eckel, president of medicine and science at the American Diabetes Association. “We could be dealing with an entirely new form of diabetes.”

‘ABSOLUTELY TERRIFYING’ DIAGNOSIS

Type 1 diabetes occurs when the body’s immune system mistakenly destroys insulin-producing cells in the pancreas, preventing the regulation of blood sugar levels. About 1.6 million Americans have the disease.

Type 2 diabetes is more prevalent, afflicting about 30 million Americans. Those patients still produce insulin,

Read More
health

Substance in Tears Could Be Used for Diabetes Monitoring



Dr Masakazu Aihara

Measuring glycated albumin (glycoalbumin, GA) in tears could be a future way for those with diabetes to monitor their blood sugar levels noninvasively.

In a 100-patient trial, levels of GA in tears were found to be strongly correlated (r = .722; P < .001) with those in the blood.

“GA levels in blood are widely measured in clinical practice in Japan,” said study investigator Masakazu Aihara, MD, PhD, in an interview.

“It’s a biomarker that reflects the 2-week average blood glucose level like fructosamine,” explained the researcher from the department of diabetes and metabolic diseases in the Graduate School of Medicine at the University of Tokyo.

This could make it a better biomarker for detecting earlier changes in blood glucose than glycated hemoglobin (HbA1c), which reflects changes in blood glucose over the preceding 2-3 months.

Prior studies had shown that glucose levels can be measured in tear samples and that tear glucose levels correlated with blood glucose levels, Aihara and fellow researchers observed in a poster presentation at the virtual annual meeting of the European Association for the Study of Diabetes.

“While looking for noninvasive diabetes-related markers, we found that tears contained albumin. Based on this fact, we thought that GA could be measured in tears,” Aihara explained.

Using tears to test for biomarkers is not a new idea – tears not only protect the eye, they contain a variety of large proteins, and their composition can change with disease. Indeed, researchers have been looking at their usefulness in helping find biomarkers for Parkinson’s disease and diabetic peripheral neuropathy.

During their study, Aihara and associates collected tear and blood samples at the same time. Tear samples were assessed using liquid chromatography (LC) and mass spectrometry (MS). An enzymic method was used to measure GA levels in blood. Several diagnosis assay kits for GA are sold in Japan, Aihara said, and at least one of these has U.S. Food and Drug Administration approval.

Multiple regression analysis revealed that the correlation between GA levels in tears and in blood was maintained even after adjustment for age, gender, nephropathy stage, and obesity (P < .001). The results obtained from the tests were thought unlikely to be affected by any changes in the concentration or dilution of tear samples.

“Since GA levels in blood are clinically used in all types of diabetes, GA levels in tears is also expected to be useful in all types of diabetes,” Aihara said, noting that the effects of receiving treatment on GA levels in tears is something that he would like to look at.

The team would also like to optimize how tear samples are collected and reduce the volume of tears that are required for analysis. At the moment tears are collected via a dropper and about 100 mcL of tear fluid is required for measurement.

“At present, it is difficult to measure for dry eye patients because sufficient tears cannot be collected, but if the required amount of tears decreases

Read More
health

Doctors Probe Whether COVID-19 Is Causing Diabetes | Top News

(Reuters) – Mario Buelna, a healthy 28-year-old father, caught a fever and started having trouble breathing in June. He soon tested positive for COVID-19.

Weeks later, after what had seemed like a recovery, he felt weak and started vomiting. At 3 a.m. on Aug. 1, he passed out on the floor of his home in Mesa, Arizona.

Paramedics rushed him to a nearby hospital, where doctors put him in intensive care after saving him from a coma. They told him he could have died. Their diagnosis – type 1 diabetes – stunned and frightened him. He had no history of the disease.

“COVID triggered it,” Buelna said the doctors told him.

Buelna’s ordeal and similar cases reflect a new worry about the dangerous relationship between diabetes and COVID-19 that’s being urgently studied by doctors and scientists around the world. Many experts are convinced that COVID-19 can trigger the onset of diabetes – even in some adults and children who do not have the traditional risk factors.

It’s already been well-documented that people with diabetes face much higher risks of severe illness or death if they contract COVID-19. In July, U.S. health officials found that nearly 40% of people who have died with COVID-19 had diabetes. Now, cases like Buelna’s suggest the connection between the diseases runs both ways.

“COVID could be causing diabetes from scratch,” said Dr. Francesco Rubino, a diabetes researcher and chair of metabolic and bariatric surgery at King’s College London.

Rubino is leading an international team that is collecting patient cases globally to unravel one of the biggest mysteries of the pandemic. Initially, he said, more than 300 doctors have applied to share cases for review, a number he expects to grow as infections flare up again.

“These cases are coming from every corner of the world and every continent,” Rubino told Reuters.

In addition to the global registry, the U.S. National Institutes of Health is financing research into how the coronavirus may cause high blood sugars and diabetes.

In these situations, symptoms can escalate quickly and become life threatening. These cases may take months to surface after exposure to COVID-19, so the full extent of the problem and the long-term ramifications may not be known until well into next year. More intensive research is needed to definitively prove, beyond the mounting anecdotal evidence, that COVID-19 is triggering diabetes on a wide scale.

“We have more questions than answers right now,” said Dr. Robert Eckel, president of medicine and science at the American Diabetes Association. “We could be dealing with an entirely new form of diabetes.”

‘ABSOLUTELY TERRIFYING’ DIAGNOSIS

Type 1 diabetes occurs when the body’s immune system mistakenly destroys insulin-producing cells in the pancreas, preventing the regulation of blood sugar levels. About 1.6 million Americans have the disease.

Type 2 diabetes is more prevalent, afflicting about 30 million Americans. Those patients still produce insulin, but over time their cells become insulin-resistant, allowing blood sugar to rise.

Type 1 diabetes cases have previously been associated with other

Read More
health

Hemoglobin Testing Market | Growing Incidence of Diabetes Worldwide to Boost Market Growth

The global hemoglobin testing market size is poised to grow by USD 612.82 million during 2020-2024, progressing at a CAGR of almost 8% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201016005222/en/

Technavio has announced its latest market research report titled Global Hemoglobin Testing Market 2020-2024 (Graphic: Business Wire)

Globally, the prevalence of diabetes has significantly increased over the decades. This can be attributed to sedentary lifestyles, obesity, and lack of physical activity. The prevalence of diabetes is growing significantly in countries across the Middle East such as Iran, where around 24% of the people aged over 40 have diabetes. In the UAE, more than 16% of the total population aged 20-79 years had diabetes in 2019. The rising prevalence of diabetes has increased the demand for effective and advanced hemoglobin testing devices to monitor glucose levels, thereby driving the growth of the market.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Report Highlights:

  • The major hemoglobin testing market growth came from the healthcare centers segment in 2019. This is due to the increasing number of hospitals in developing countries and the growing trend of medical tourism.

  • North America was the largest market for hemoglobin testing in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. This is attributed to the increasing prevalence of obesity and diabetes in the region.

  • The global hemoglobin testing market is fragmented. Abbott Laboratories, ACON Laboratories Inc., Bayer AG, Bio-Rad Laboratories Inc., Danaher Corp., Diazyme Laboratories Inc., EKF Diagnostics Holdings Plc, F. Hoffmann-La Roche Ltd., Siemens AG, and Thermo Fisher Scientific Inc. are some of the major market participants. To help clients improve their market position, this hemoglobin testing market forecast report provides a detailed analysis of the market leaders.

  • As the business impact of COVID-19 spreads, the global hemoglobin testing market 2020-2024 is expected to have neutral growth. As the pandemic spreads in some regions and plateaus in other regions, we revaluate the impact on businesses and update our report forecasts.

Read the full report here: https://www.technavio.com/report/hemoglobin-testing-market-industry-analysis

Growing preference for home care settings will be a Key Market Trend

Over the years, the demand for homecare blood testing devices has increased across the globe. This is because home care testing devices provide faster results and help patients better manage their disease. They also reduce the overall investigation time and the number of visits to hospitals outpatient department and diagnostic laboratories. This has encouraged vendors in the market to offer a wide range of diagnostics devices that are ideal for home use. For instance, PTS

Read More